Core Insights - PureTech has presented new Phase 2b analyses that demonstrate the consistent safety and efficacy of Deupirfenidone in older patients with Idiopathic Pulmonary Fibrosis (IPF) [1] Group 1: Safety and Efficacy - The analyses indicate that Deupirfenidone shows a favorable safety profile in older patients [1] - Efficacy results suggest that Deupirfenidone effectively slows disease progression in this demographic [1] Group 2: Patient Demographics - The focus of the study is on older patients, highlighting the need for effective treatments in this age group suffering from IPF [1]